Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Steroid Hormones Induce HMG1 Overexpression and Sensitize Breast Cancer Cells to Cisplatin and Carboplatin

Qing He, Cynthia H. Liang and Stephen J. Lippard
Proceedings of the National Academy of Sciences of the United States of America
Vol. 97, No. 11 (May 23, 2000), pp. 5768-5772
Stable URL: http://www.jstor.org/stable/122531
Page Count: 5
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Steroid Hormones Induce HMG1 Overexpression and Sensitize Breast Cancer Cells to Cisplatin and Carboplatin
Preview not available

Abstract

Cisplatin is an anticancer drug that has enjoyed remarkable success against testicular tumors, but dose limiting side-effects have limited its application against a broader range of cancers. Previous studies have shown that high-mobility group (HMG) domain proteins such as HMG1 sensitize cells to cisplatin by shielding its major DNA adducts from nucleotide excision repair. Estrogen treatment increases HMG1 mRNA levels in breast cancer MCF-7 cells. Herein, we describe that treatment of human cancer cells having steroid hormone receptors with the appropriate hormone, estrogen and/or progesterone, significantly increases the potency of cisplatin and its analogue carboplatin by causing the overexpression of HMG1. These findings suggest that the proper combination of these drugs, which are already approved by the Food and Drug Administration, could have potential benefit in treating tumors such as ovarian or breast that carry the hormone receptors.

Page Thumbnails

  • Thumbnail: Page 
5768
    5768
  • Thumbnail: Page 
5769
    5769
  • Thumbnail: Page 
5770
    5770
  • Thumbnail: Page 
5771
    5771
  • Thumbnail: Page 
5772
    5772